Abeceline mesylate, as a therapeutic drug for breast cancer, can also inhibit the level of proinflammatory cytokines mediated by LPS by downregulating AKT/STAT3 signal transduction, and improve the status of AD diseases.65 The gene discussed is STAT3; the disease is breast carcinoma.